Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

Origin Enterprises plc ( ($GB:OGN) ) has issued an announcement. Origin Enterprises has announced that independent non executive director Alan Ralp...

Origin Director Alan Ralph Appointed to Cairn Homes Board

In a report released on May 8, Lucas Glemser from Berenberg Bank maintained a Buy rating on Logitech, with a price target of CHF115.00. The company...

Berenberg Bank Remains a Buy on Logitech (LOGI)

In a report released today, Joern Iffert from UBS maintained a Hold rating on Logitech, with a price target of CHF80.00. According to TipRanks, Iff...

Logitech (LOGI) Gets a Hold from UBS

Wedbush analyst reiterated a Buy rating on Logitech today and set a price target of $135.00. The word on The Street in general, suggests a Moderate...

Wedbush Sticks to Their Buy Rating for Logitech (LOGI)

Traders seeking the latest stock market stories for Friday will find them in our daily wrap-up.


Morning News Wrap-Up, 4/24/26: Today’s Biggest Stock Market Stories!

Organon stock took off on reports of a $13 billion bid from Sun Pharmaceutical Industries.


Organon Stock (OGN) Surges on Reports of a $13B Bid

Origin Enterprises plc ( ($GB:OGN) ) has shared an announcement. Origin Enterprises plc has transferred 44,536 treasury shares to satisfy exercises...

Market Cap	$2.38B	P/E Ratio	4.15
52W High	$13.44	52W Low	$5.69
Div Yield	8.0%	Payout Ratio	47.3%
EPS Growth 3Y	-41.6%	52W Position	99.5%
Overall Score	64	Value Score	100
Quality Score	36	Technical Score	58

EPS Current Est	$3.23	EPS Next Est	$3.44
EPS Growth Est	+6.5%	DPS Growth 3Y	-32.8%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$13.40	+0.30%	3.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$13.40	+0.3%	3.28M
3
4
5
6

OGN

OGN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel